FDA approves 1st immunotherapy drug to treat breast cancer

News
FDA--web_1531477148466.jpg

The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer.

Swiss drugmaker Roche’s Tecentriq was OK’d Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. It’s to be given with chemotherapy, the standard treatment.

Mount Sinai breast cancer specialist Dr. Amy Tiersten in New York called it “tremendously exciting news.”

Approved for two other cancers, Tecentriq works by boosting the immune system’s ability to spot and kill cancer cells.

In a study of 900 women, the benefits were modest. Those who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone. The combo caused nerve pain, nausea and other side effects.

Tecentriq costs about $13,400 per month.

Copyright 2019 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories

Win Clemson Tickets
Things to Do
Color Your Weather
Pro Football Challenge
wspa news app free for download choose your store below
download the wspa news app from the apple app store
download the wspa news app from the google play store